Mutant Fibulin-3 Causes Proteoglycan Accumulation and Impaired Diffusion Across Bruch’s Membrane

Astrid Zayas-Santiago,1 Samuel D. Cross,2 James B. Stanton,3 Alan D. Marmorstein,2 and Lihua Y. Marmorstein2

1Department of Pathology & Laboratory Medicine, Universidad Central del Caribe, Bayamón, Puerto Rico
2Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, United States
3Department of Ophthalmology & Vision Science, University of Arizona, Tucson, Arizona, United States

PURPOSE. The mutation R345W in EFEMP1 (fibulin-3) causes macular degeneration. This study sought to determine whether proteoglycan content and diffusion across Bruch’s membrane are altered in Efemp1R345W mice carrying this mutation or in Efemp1+/− mice.

METHODS. Proteoglycans in mouse Bruch’s membranes were stained with Cupromeronic Blue (CB). Heparan sulfated proteoglycan (HSPG) and chondroitin/dermatan sulfate proteoglycan (C/DSPG) distributions were visualized following treatments with chondroitinase ABC (C-ABC) or nitrous acid. Total sulfated glycosaminoglycans (sGAGs) in Bruch’s membrane/choroid (BrM/Ch) were measured with dimethylmethylene blue (DMMB). Matrix metalloproteinase (MMP)-2, MMP-9, and tissue inhibitor of metalloproteinase (TIMP)-3 were examined by immunofluorescence and quantified using Image J. Molecules with different Stokes radius (R̅) were allowed simultaneously to diffuse through mouse BrM/Ch mounted in a modified Ussing chamber. Samples were quantified using gel exclusion chromatography.

RESULTS. HSPGs and C/DSPGs were markedly increased in Efemp1R345W Bruch’s membrane, and MMP-2 and MMP-9 were decreased, but TIMP-3 was increased. Diffusion across Efemp1R345W Bruch’s membrane was impaired. In contrast, the proteoglycan amount in Efemp1+/− Bruch’s membrane was not significantly different, but the size of proteoglycans was much larger. MMP-2, MMP-3, and TIMP-3 levels were similar to that of Efemp1+/− mice, but they were localized diffusely in retinal pigment epithelium (RPE) cells instead of Bruch’s membrane. Diffusion across Efemp1+/− Bruch’s membrane was enhanced.

CONCLUSIONS. Mutant fibulin-3 causes proteoglycan accumulation, reduction of MMP-2 and MMP-9, but increase of TIMP-3, and impairs diffusion across Bruch’s membrane. Fibulin-3 ablation results in altered sizes of proteoglycans, altered distributions of MMP-2, MMP-9, and TIMP-3, and enhances diffusion across Bruch’s membrane.

Keywords: age-related macular degeneration, Malattia Leventinese, EFEMP1 (fibulin-3), proteoglycans, diffusion

Bruch’s membrane is a thin layer of connective tissue interposed between the RPE and the choriocapillaris. It serves as a semipermeable filtration barrier for bidirectional diffusion of nutrients and metabolites between the outer retina and the choriocapillaris. Bruch’s membrane contains five parts distinguishable by electron microscopy: the basement membrane of the RPE, inner collagenous zone, elastic fiber zone, outer collagenous zone, and the basement membrane of the endothelium of the choriocapillaris. The ground substance in Bruch’s membrane is composed largely of sulfated proteoglycans. These anionic proteoglycans contribute to charge-selective properties of Bruch’s membrane associated with diffusion. It has been suggested that the sulfated glycosaminoglycan (sGAG) side chains of proteoglycans provide an electrolytic barrier to diffusion. Thus, alterations in the proteoglycan content of Bruch’s membrane could influence its diffusion properties, cause retention of materials in Bruch’s membrane, and ultimately disrupt the function of the RPE and outer retina leading to disease. Sub-RPE deposits between the RPE and Bruch’s membrane (basal laminar deposit [BLamD]) or within Bruch’s membrane (basal linear deposits and drusen) are a hallmark of age-related macular degeneration (AMD), the most common cause of incurable blindness in developed countries. Although it is still not clear how these deposits develop, one hypothesis is that the sub-RPE deposits may result from a change in the ability of materials to diffuse across Bruch’s membrane. Similar to AMD, an autosomal dominant macular degeneration Malattia Leventinese/Doyne’s honeycomb retinal dystrophy (ML/DHRD) is also characterized by the presence of sub-RPE deposits. ML/DHRD is caused by the mutation R345W in fibulin-3, a basement membrane glycoprotein encoded by the gene EGF containing fibulin-like extracellular matrix protein 1 (EFEMP1). Fibulin-3 is a member of the fibulin family. Fibulins are a family of extracellular matrix (ECM) proteins that share an elongated structure containing tandem arrays of calcium-binding epidermal growth factor (EGF)-like domains and a carboxy-terminal fibulin-type.
The functions of fibulins are not completely understood yet, but a common feature among them is that they have a high affinity for proteoglycans. \( \text{Efemp}^+/+ \) mice and \( \text{Efemp}^+/- \) mice were generated previously. \( \text{Efemp}^{+/+} \) and \( \text{Efemp}^{+/-} \) mice were handled in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research, using protocols approved by the Institutional Animal Care and Use Committee of the University of Arizona or Mayo Clinic. Animals were housed under standard conditions and maintained on a 12-hour light/dark cycle with free access to food and water.

Proteoglycan Distribution in Bruch's Membrane

Eyes from 9-month-old wild-type (\( \text{Efemp}^{+/+} \)) and \( \text{Efemp}^{+/-} \) mice were fixed at 4°C in 1% formaldehyde, 2% glutaraldehyde, 0.1 M phosphate buffer, pH 7.4. Chorioretinal tissues were dissected from fixed eyes, cut into strips, and divided into four groups for enzymatic or nitrous acid treatment: (group 1) control group without enzyme or nitrous acid treatment; (group 2) C-ABC (Sigma-Aldrich Corp., St. Louis, MO, USA) treatment; (group 3) nitrous acid (Sigma-Aldrich Corp.) treatment; and (group 4) combinational treatment with both C-ABC and nitrous acid. For C-ABC treatment, tissue strips were incubated with 1 unit/mL C-ABC in 0.25 M Tris buffer containing 0.05% BSA, 5 mM benzamidine-HCl, and 0.1 M 6-amino-caproic acid, pH 8.0, at 37°C for 24 hours. For nitrous acid treatment, tissue strips were incubated in a nitric acid solution containing 5% sodium nitrite, 35% acetic acid, 5 mM benzamidine-HCl, and 0.1 M 6-amino-caproic acid for 90 minutes at room temperature. Each group of tissue strips was then stained with 0.05% CB (Sigma-Aldrich Corp.) in 25 mM sodium acetate, 0.2 M MgCl₂ and 2.5% glutaraldehyde, pH 5.7 overnight as described. After staining, tissue strips were processed for transmission electron microscopy. Thin sections were cut with a Reichert Ultracut microtome, stained with uranyl acetate and lead citrate, and imaged with a Philips CM-12 electron microscope equipped with an AMT CCD camera (Advanced Microscopy Techniques Corp., Danvers, MA, USA).

CB-stained proteoglycan filaments were quantified by counting the filaments from different view fields at the same magnification. Specimens from three individual mice for each genotype were included in the filament quantification. Three sections from each specimen were used, and 10 different fields from each section were counted. The numbers of filaments from \( \text{Efemp}^{+/+} \) or \( \text{Efemp}^{+/-} \) mice were compared with those in \( \text{Efemp}^{+/-} \) mice using a Student’s t-test. Proteoglycan filament lengths were measured using the Adobe Photoshop ruler tool. Ten different filaments per field for each genotype (HSPG or C/DSGP) were measured. Due to their small size, filament lengths were measured to the nearest 5 nm.

sGAG Quantification Assay

After mice were killed with CO₂ asphyxiation, eyes from 9-month-old \( \text{Efemp}^{+/+} \), \( \text{Efemp}^{+/-} \), and \( \text{Efemp}^{+/-} \) mice were enucleated, and the lens and anterior segments were removed. The retina was detached using forceps, the eyecup filled with PBS buffer, and the RPE was removed using a fine camel’s hair brush. The BrM/Ch was detached from the sclera, weighed, and minced. Five sets of BrM/Ch samples from five mice per genotype (\( \text{Efemp}^{+/+} \), \( \text{Efemp}^{+/-} \), or \( \text{Efemp}^{+/-} \)) were analyzed. Samples were digested with 300 μg papain (Sigma-Aldrich Corp.) in 200 μl of 0.1 M phosphate buffer (pH 6.8) containing 1 mM EDTA and 2 mM dithiothreitol at 60°C for 2 hours. Samples were diluted with 10 mM iodoacetate acid and

Methods

Mice

\( \text{Efemp}^{+/-} \) and \( \text{Efemp}^{+/-} \) mice were generated previously. \( \text{Efemp}^{+/-} \) mice were handled in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research, using protocols approved by the Institutional Animal Care and Use Committee of the University of Arizona or Mayo Clinic. Animals were housed under standard conditions and maintained on a 12-hour light/dark cycle with free access to food and water.
50 mM Tris/HCl (pH 8.0). The sGAG content in papain-digested samples was measured by colorimetric assay with DMMB using an assay kit (Amsbio, Cambridge, MA, USA) according to the manufacturer’s instructions. sGAG measurements from Efemp1ki/ki or Efemp1+/− mice were compared with those in Efemp1+/− mice using a Student’s t-test.

**Immunofluorescence**

Eyes from 9-month-old Efemp1+/−, Efemp1ki/ki, and Efemp1+/− mice were fixed in 4% paraformaldehyde. Immunofluorescence staining of 10-μm frozen sections of mouse eyes was performed as previously described using a rabbit polyclonal antibody against MMP-2 (Abcam, Cambridge, MA, USA), MMP-9 (Abcam), TIMP-3 (Abcam), or fibulin-3. A goat anti-rabbit IgG antibody against MMP-2 (Abcam, Cambridge, MA, USA), MMP-9 (Abcam), TIMP-3 (Abcam), or fibulin-3 (35) was used as a secondary antibody (Invitrogen, Carlsbad, CA, USA). Cell nuclei were stained with 4’,6-diamidino-2-phenylindole (DAPI). Sections were examined and photographed using a Nikon E6000 microscope (Melville, NY, USA) equipped with a CCD camera.

Quantification of immunofluorescence was performed using Image J software (National Institutes of Health, Bethesda, MD, USA). Sections from three mice (n = 3) per genotype (Efemp1+/−, Efemp1ki/ki, or Efemp1+/−) were used. Three images taken from three randomly selected areas in each staining section were measured. In each image, the outline of the RPE layer and Bruch’s membrane was drawn, and the area, mean fluorescence, and background readings were measured. The total fluorescence was calculated as integrated density subtracting (area of selected sections × mean fluorescence of background readings).

Fluorescence from Efemp1ki/ki or Efemp1+/− mice was compared with that in Efemp1+/− mice using a Student’s t-test.

**Diffusion Assay**

The BrM/Ch prepared from 9- or 18-month-old Efemp1+/−, Efemp1ki/ki, and Efemp1+/− mice was mounted between two pieces of X-ray film, which had corresponding 1.0-mm diameter drilled holes and were coated with a thin film of silicon grease. Diffusion of molecules through mouse BrM/Ch was studied using a dual Ussing chamber model U2500 (Warner Instruments, Hamden, CT, USA). The BrM/Ch-X-ray film “sandwich” was mounted, separating the two chambers with only the 1.0-mm diameter circle of BrM/Ch allowing communication between them. Four molecules with different Rr were selected for their ability to separate cleanly by gel exclusion chromatography: cytosine (molecular weight [MW] = 110.1, Rs < 1.0 nm; Sigma-Aldrich Corp.), RNase A (MW = 13,700, Rs = 1.72 nm; Teknova, Hollister, CA, USA), human serum albumin (MW = 66,382, Rs = 3.5–4.5 nm; EMD Chemicals, Gibbstown, NJ, USA), and horse spleen ferritin (MW = 450,000, Rs = 6.15 nm; EMD Chemicals). A mixture of these molecules dissolved in PBS with 1 mM MgCl2 and 0.1 mM CaCl2 (PBS-CM) was added to the reservoir on the BrM side of the tissue with only PBS-CM on the Ch side.

**Flux and Permeability Coefficients**

Flux and permeability coefficients were calculated as previously described. Molecules were quantified after 48 hours using gel exclusion chromatography with a 1.6 × 60 cm Hi-Prep Sephacryl S-500HR (Amersham Biosciences, Piscataway, NJ, USA) column equilibrated with PBS-CM. The column was developed at a linear flow rate of 15 mL cm−1 hr−1 using an AKTA prime chromatography system controlled by PrimeView software (GE Healthcare Life Sciences, Pittsburgh, PA, USA). Peaks were detected by their absorbance at 280 nm, and peak areas were determined by integration using PrimeView software. Solute concentrations were quantified by linear regression analysis using peak areas derived from known quantities of each test molecule. Flux (J) was calculated using the equation J = (C)/(A × t) where C = accumulated molar concentration, A = the area (cm²) of the exposed tissue (0.000785 cm²), and t = 48 hours. Permeability coefficients (P) were calculated using Fick’s first law P = (J/L)/Ac where L is the thickness of the BrM/Ch preparation and Ac describes the difference in moles of molecules between the two compartments of the Ussing chamber.

**RESULTS**

Rod-like filaments representing sulfated proteoglycans were observed at high magnifications under electron microscopy in Bruch’s membrane of 9-month-old Efemp1+/−, Efemp1ki/ki, and Efemp1+/− mice after CB staining (Fig. 1). The size and number of filaments were different in mice with different Efemp1 genotypes (Fig. 1). In Efemp1+/− Bruch’s membrane, filaments with an average length of 50 nm were observed in the collagenous/elastic fibrous layers, and filaments with an average length of 40 nm were observed in the basement membranes of the RPE and endothelium of choriocapillaris (Figs. 1A, 1a1, 1a2; Table 1). Smaller sizes of filaments may represent the same type of filaments cut shorter during sectioning or only partially visible in any given microscopic viewing field. Filaments in the fibrous layers were eliminated by C-ABC treatment (Fig. 2), indicating that they were C/DSPGs. Filaments in the basement membranes were removed by nitric acid treatment (Fig. 3), indicating that those filaments were HSPGs. Combined treatment of both C-ABC and nitrous acid eliminated all the filaments from Bruch’s membrane (Fig. 4). This indicates that all the filaments observed were either HSPGs or C/DSPGs.

**Proteoglycan Accumulation in Bruch’s Membrane of Efemp1ki/ki Mice**

Markedly increased filaments were observed in Bruch’s membrane of Efemp1ki/ki mice (Figs. 1B, 1b1, 1b2). By counting the filaments from different view fields at the same magnification, we determined that there were on average three times as many filaments in Efemp1ki/ki Bruch’s membrane as those in Efemp1+/− Bruch’s membrane (Table 2).

After C-ABC treatment, filaments with an average length of 40 nm (Table 1) representing HSPGs remained in the basement membranes of the RPE and endothelium of choriocapillaris in Efemp1ki/ki mice (Fig. 2). There were 2.35 times as many filaments in Efemp1ki/ki basal membranes as those in Efemp1+/− mice (Table 2). After nitrous acid treatment, filaments with an average length of 50 nm (Table 1) representing C/DSPGs remained in the fibrous layers of Efemp1ki/ki Bruch’s membrane (Fig. 3). There were 4.15 times as many filaments in Efemp1ki/ki fibrous layers as those in Efemp1+/− fibrous layers (Table 2). Combined treatment of C-ABC and nitrous acid eliminated all the filaments from Efemp1ki/ki Bruch’s membrane (Fig. 4), indicating that all the filaments observed were either HSPGs or C/DSPGs.

Biochemical analysis by DMMB colorimetric assays revealed that total sGAG content in 9-month-old Efemp1ki/ki BrM/Ch was significantly higher than that of Efemp1+/− mice (Fig. 5). The average amount of sGAGs in Efemp1ki/ki BrM/Ch was 15.89 μg/mg wet tissue weight, comparing to 10.15 μg/mg in Efemp1+/− mice.
Different Sizes of Proteoglycans in Bruch’s Membrane of Efemp1<sup>−/−</sup> Mice

In Efemp1<sup>−/−</sup> mice, there were slightly more filaments observed in Bruch’s membrane than in Efemp1<sup>+/+</sup> mice, but the difference was not statistically significant (Table 2). However, the size of filaments in Efemp1<sup>−/−</sup> Bruch’s membrane was strikingly larger (Figs. 1C, 1c1, 1c2). After CABC treatment, filaments with an average length of 120 nm (Table 1) representing HSPGs were observed in Efemp1<sup>−/−</sup> basement membranes of the RPE and endothelium of choriocapillaris.

**TABLE 1.** Proteoglycan Sizes in Efemp1<sup>+/+</sup>, Efemp1<sup>+/−</sup>, or Efemp1<sup>−/−</sup> Bruch’s Membrane

| PG Type | Efemp1<sup>+/+</sup> | Efemp1<sup>+/−</sup> | Efemp1<sup>−/−</sup> |
|---------|----------------------|----------------------|----------------------|
| HSPG    | 40 ± 10 nm           | 40 ± 15 nm           | 120 ± 30 nm          |
| C/DSPG  | 50 ± 10 nm           | 50 ± 15 nm           | 105 ± 20 nm          |

Proteoglycan filament length = mean ± SD. n = 3 mice per genotype.
(Fig. 2). After nitrous acid treatment, filaments with an average length of 105 nm (Table 1) representing C/DSPGs were observed in the fibrous layers of Efemp1$^{1/\neg}$ Bruch’s membrane (Fig. 3). Despite the different sizes, combined treatment of C-ABC and nitrous acid eliminated all the filaments from Efemp1$^{1/\neg}$ Bruch’s membrane (Fig. 4), indicating that all the filaments were either HSPGs or C/DSPGs.

Results of DMBB assays showed that total sGAG content in BrM/Ch from 9-month-old Efemp1$^{+/\neg}$ mice was similar to that of Efemp1$^{1/\neg}$ mice (Fig. 5). The average amount of sGAGs in Efemp1$^{1/\neg}$ BrM/Ch was 11.04 μg/mg.

Altered Levels and Distributions of MMP-2, MMP-9, and TIMP-3 in the RPE and Bruch’s Membrane of Efemp1$^{ki/ki}$ and Efemp1$^{1/\neg}$ Mice

Immunofluorescence revealed that MMP-2, MMP-9, and TIMP-3 were localized to the basal side of the RPE along Bruch’s membrane in Efemp1$^{1/\neg}$ and Efemp1$^{ki/ki}$ mice (Fig. 6A). TIMP-3 and fibulin-3 were co-localized together and had a complete overlap-staining pattern in these mice (Fig. 6A). However, quantification of immunofluorescence showed that the levels of both MMP-2 and MMP-9 were significantly reduced in Efemp1$^{ki/ki}$ mice (Fig. 6B). In contrast, TIMP-3’s level was significantly increased in Efemp1$^{ki/ki}$ mice (Fig. 6B). Without fibulin-3 in Efemp1$^{1/\neg}$ mice, MMP-2, MMP-9, and TIMP-3 had a drastically different pattern of distribution. All three proteins had a diffuse distribution in RPE cells (Fig. 6A). This suggests that fibulin-3 may normally function to anchor these proteins to Bruch’s membrane. Quantification of immunofluorescence showed that the levels of all three proteins in the Efemp1$^{1/\neg}$ RPE and Bruch’s membrane were slightly lower than that in Efemp1$^{1/\neg}$ mice, but the difference was not statistically significant (Fig. 6B).

**Different Diffusion Rates Across Mouse Bruch’s Membrane of Efemp1$^{1/\neg}$, Efemp1$^{ki/ki}$, and Efemp1$^{1/\neg}$ Mice**

We previously established a system using a modified Ussing chamber coupled with quantitative gel exclusion chromatography to study the diffusion of multiple molecules with different Rs through small samples (< 2 mm$^2$) of Bruch’s membrane. Here we used this system to measure differences in the diffusion of four molecules through Bruch’s membrane of 9- and 18-month-old Efemp1$^{1/\neg}$, Efemp1$^{ki/ki}$, and Efemp1$^{1/\neg}$ mice in the BrM to Ch direction. We established a concentration gradient of all four molecules across BrM/Ch and applied Fick’s first law to calculate the flux and permeability coefficient of each molecule as described previously. The flux of each molecule remained constant, and the concentration gradient was not significantly influenced by the diffusion of molecules throughout the time course of each experiment. Flux and permeability coefficient decreased with increasing Rs (Fig. 7).

For Efemp1$^{1/\neg}$ tissue ($n = 5$ mice per age), cytosine had a flux of $5.33 \times 10^4$ (9 months) and $2.99 \times 10^5$ mmol cm$^{-2}$ h$^{-1}$ (18 months), and a permeability coefficient of 0.94 (9 months)
and 0.47 cm\(^{-2}\) h\(^{-1}\) (18 months). Ferritin had a flux of 1.32 (9 months) and 0.86 nmol cm\(^{-2}\) h\(^{-1}\) (18 months), and a permeability coefficient of 9.25 \times 10^{-5} (9 months) and 2.38 \times 10^{-5} cm\(^{-2}\) h\(^{-1}\) (18 months). Flux and permeability coefficient of each molecule were higher for 9-month-old than 18-month-old tissue (Fig. 7).

We found both flux and permeability coefficients of each molecule were significantly \(P < 0.05\) decreased for BrM/Ch samples from \(\text{Efemp}^{1+/+}\) mice \((n = 5\) for 9 months old, and \(n = 6\) for 18 months old) (Fig. 7). Cytosine had a flux of 8.54 (9 months) and 6.71 nmol cm\(^{-2}\) h\(^{-1}\) (18 months), and a permeability coefficient of 6.92 \times 10^{-4} (9 months) and 2.24 \times 10^{-4} cm\(^{-2}\) h\(^{-1}\) (18 months). Ferritin had a flux of 4.80 \times 10^{-2} (9 months) and 1.47 \times 10^{-2} nmol cm\(^{-2}\) h\(^{-1}\) (18 months), and a permeability coefficient of 1.01 \times 10^{-6} (9 months) and 3.13 \times 10^{-7} cm\(^{-2}\) h\(^{-1}\) (18 months). This indicates that diffusion across Bruch’s membrane of \(\text{Efemp}^{1+/+}\) mice was markedly decreased, with ferritin virtually impermeable at both 9 and 18 months of ages.

In contrast to \(\text{Efemp}^{1+/+}\) mice, we found increased flux and permeability coefficient of each molecule for BrM/Ch samples from \(\text{Efemp}^{1+/+}\) mice \((n = 6\) for 9 months old, and \(n = 8\) for 18 months old) (Fig. 7). Cytosine had a flux of 1.13 \times 10^{3} (9 months) and 4.79 \times 10^{3} nmol cm\(^{-2}\) h\(^{-1}\) (18 months), and a permeability coefficient of 5.30 (9 months) and 2.93 cm\(^{-2}\) h\(^{-1}\) (18 months). Ferritin had a flux of 3.98 nmol (9 months) and 2.19 nmol cm\(^{-2}\) h\(^{-1}\) (18 months), and a permeability coefficient of 5.56 \times 10^{-4} (9 months) and 1.12 \times 10^{-4} cm\(^{-2}\) h\(^{-1}\) (18 months). This indicates that diffusion across Bruch’s membrane of \(\text{Efemp}^{1+/+}\) mice was increased at both 9 and 18 months of ages. The permeability coefficient was similar for albumin and ferritin for BrM/Ch samples from either \(\text{Efemp}^{1+/+}\) or \(\text{Efemp}^{1+/+}\) mice (Fig. 7B), suggesting that the ferritin is near the physical size exclusion limit of Bruch’s membrane for these mice.

**Table 2.** Proteoglycan Distributions in \(\text{Efemp}^{1+/+}\), \(\text{Efemp}^{1+/+}\), and \(\text{Efemp}^{1+/+}\) Bruch’s Membrane

| PG Type | \(\text{Efemp}^{1+/+}\) | \(\text{Efemp}^{1+/+}\) | \(\text{Efemp}^{1+/+}\) |
|---------|----------------|----------------|----------------|
| Total SPG | 906 ± 106\(^{a}\) | 906 ± 106\(^{a}\) | 348 ± 57 |
| HSPG | 183 ± 20 | 431 ± 31\(^{a}\) | 197 ± 19 |
| C/DSPG | 96 ± 26 | 398 ± 46\(^{a}\) | 113 ± 22 |

Proteoglycan filaments per field. The number for each category is the average of 10 fields of each section (three sections) from each specimen (three specimens) ± SD. \(n = 3\) mice per genotype. \(^{a}\)\(P < 0.05\).
a broad range of proteoglycanases, is significantly increased. Without fibulin-3 in Efemp1+/− mice, MMP-2, MMP-9, and TIMP-3 are diffusely localized in RPE cells instead of Bruch’s membrane, suggesting that fibulin-3 may normally be an anchor for these proteins to Bruch’s membrane. Fibulin-3 has ECM enzyme inhibitory activity.22,25,42 We hypothesize that it regulates proteoglycan turnover in Bruch’s membrane by controlling proteoglycanase activities. In the absence of fibulin-3, proteoglycans normally present in Bruch’s membrane may be degraded. The different sizes of proteoglycans in Efemp1+/− mice may be derived from a compensatory effect induced by the lack of normal proteoglycans. They may be different types of HSPGs or C/DSPGs or same core proteoglycans with different levels of sulfation. The R345W mutation does not impair fibulin-3’s activity but makes the protein more resistant to degradation leading to its accumulation.32 In Efemp1+/− mice, fibulin-3 is accumulated in Bruch’s membrane. This accumulation could provide a high level of localized inhibitory activity on proteoglycanase(s) and cause proteoglycan accumulation in Bruch’s membrane. Fibulin-3 is overexpressed by senescent cells in aging tissues.45,46 It accumulates in Bruch’s membrane of both ML/DHRD and AMD donor eyes.32 There is no fibulin-3 mutation found in AMD patients.13,32 This supports the idea that elevated fibulin-3 activity from fibulin-3 accumulation due to mutation or aging causes pathologic changes associated with sub-RPE deposits.

Studies on the composition of sub-RPE deposits have found that lipoproteins, cholesterol, and products of the complement system are common components of sub-RPE deposits.45-52 This leads to an ocular “response-to-retention” hypothesis for sub-RPE deposit formation reminiscent of that for atherosclerosis,45 which proposes that lipoproteins are retained on proteoglycans in the arterial intima, become modified, and then elicit an inflammatory response leading to atherosclerotic plaque formation.50 We have previously found that lipid-containing particles (previously referred to as membranous debris) accumulate in linear tracks within BLMs in Efemp1+/− mice.33 Our findings here suggest that the lipid-containing particles may be trapped by the proteoglycans accumulated in Bruch’s membrane, thus, leading to the exposure of retained lipids to the high oxidant environment at the RPE/Bruch’s membrane interface. Oxidative modification of lipids triggers complement activation to remove the oxidatively damaged molecules.51 The sustained supply of lipids trapped in proteoglycans can turn complement activation into chronic inflammation with the accumulation of inflammatory products to form sub-RPE deposits.

Proteoglycans affect the diffusion properties of Bruch’s membrane. Consistent with the changes in proteoglycans in Efemp1+/− and Efemp1−/− mice, we have found that diffusion across Bruch’s membrane is impaired in Efemp1−/− mice, but enhanced in Efemp1+/− mice. Both flux and permeability coefficient decreased exponentially for all four molecules with Rs ranging from <1.0 to 6.15 nm for Efemp1−/− mice comparing to those for the wild-type mice. This suggests that the porosity of Bruch’s membrane is greatly reduced in Efemp1−/− mice. The increased amount of proteoglycans in these mice may structurally obscure pores of Bruch’s membrane, or may increase the viscosity of the fibrous layers. Impaired diffusion would hinder the removal of metabolic wastes and other molecules secreted from the RPE, and accelerate the deposition of heterogeneous materials in Bruch’s membrane of Efemp1+/−. For Efemp1−/− mice, the flux and permeability coefficient across Bruch’s membrane are more in line with those of the wild-type mice, but the increase is significant. The substantially larger sizes of proteoglycans in Efemp1−/− mice may structurally expand pore sizes of Bruch’s membrane resulting in enhanced diffusion as we observed.

In summary, our study has found that mutant fibulin-3 causes proteoglycan accumulation and impaired diffusion across Bruch’s membrane. Fibulin-3 may have specific proteoglycanase substrate(s). It would be worthwhile to investigate this in future studies. The impairment of diffusion across Bruch’s membrane would block nutrient and waste flow to and from the retina, contribute to the initiation and/or growth of sub-RPE deposits, and induce degeneration of the RPE and photoreceptors. The enhanced diffusion across Bruch’s membrane of Efemp1+/− mice suggests that reduction or elimination of fibulin-3 could be a valuable strategy in developing treatments for macular degeneration.
Acknowledgments

The authors thank Taylor Berent for technical assistance. Supported by National Institutes of Health Grants EY13847 (LYM), EY13160 (ADM), and EY21153 (ADM), The Edward N. & Della L. Thome Memorial Foundation (LYM), Mayo Foundation, and an unrestricted grant from Research to Prevent Blindness to the Department of Ophthalmology at the Mayo Clinic in Rochester, MI, USA.

Disclosure: A. Zayas-Santiago, None; S.D. Cross, None; J.B. Stanton, None; A.D. Marmorstein, None; L.Y. Marmorstein, None

References

1. Booij JC, Baas DC, Beisekeeva J, Gorgels TG, Bergen AA. The dynamic nature of Bruch’s membrane. Prog Retin Eye Res. 2010;29:1–18.
2. Guyer DR, Schachat AP, Green WR. The choroids: structural consideration. In: Ryan SJ, ed. Retina. St. Louis, MO: Mosby; 2001:29.
3. Call TW, Hollyfield JG. Sulfated proteoglycans in Bruch’s membrane of the human eye: localization and characterization using cupromeronic blue. Exp Eye Res. 1990;51:451–462.
4. Sarks SH, Sarks JP. Age-related maculopathy: nonneovascular age-related macular degeneration and the evolution of geographic atrophy. In: Ryan SJ, ed. Retina. St. Louis, MO: Mosby; 2001:1064.
5. Sarks S, Cherepanoff S, Killingsworth M, Sarks J. Relationship of basal laminar deposit and membranous debris to the clinical presentation of early age-related macular degeneration. Invest Ophthalmol Vis Sci. 2007;48:968–977.
6. de Jong PT. Age-related macular degeneration. N Engl J Med. 2006;355:1474–1485.
7. Guyer DR, Bird AC. Age changes in Bruch’s membrane and related structures. In: Ryan SJ, ed. Retina. St. Louis, MO: Mosby; 2001:1051–1063.
8. Piguet B, Haimovici R, Bird AC. Dominantly inherited drusen represent more than one disorder: a historical review. Eye. 1995;9(pt 1):34–41.
9. Marmorstein L. Association of EFEMP1 with malattia leventinese and age-related macular degeneration: a mini-review. Ophthal Genet. 2004;25:219–226.
10. Streicher T, Schmidt K, Dusek J. Hereditary drusen of Bruch’s membrane. I. Clinical and light microscopical study [in German]. Klin Monatsbl Augenheilkd. 1982;181:27–31.
11. Dusek J, Streicher T, Schmidt K. Hereditary drusen of Bruch’s membrane. II: Studies of semi-thin sections and electron microscopy results [in German]. Klin Monatsbl Augenheilkd. 1982;181:79–85.
12. Collins T. A pathological report on a case of Doyne’s choroiditis (“honeycomb” or “family choroiditis”). Ophthalmoscope. 1913;11:537–538.
13. Stone EM, Lotery AJ, Munier FL, et al. A single EFEMP1 mutation associated with both Malattia Leventinese and Doyne honeycomb retinal dystrophy. Nat Genet. 1999;22:199–202.
14. Zhang Y, Marmorstein LY. Focus on molecules: fibulin-3 (EFEMP1). Exp Eye Res. 2010;90:374–375.
15. Timpl R, Sasaki T, Kostka G, Chu ML. Fibulins: a versatile family of extracellular matrix proteins. Nat Rev Mol Cell Biol. 2003;4:479–489.
16. Djokic J, Fagotto-Kaufmann C, Bartels R, Nelea V, Reinhardt DP. Fibulin-3, -4, and -5 are highly susceptible to proteolysis, interact with cells and heparin, and form multimers. J Biol Chem. 2013;288:22821–22835.
17. Lee NV, Rodriguez-Manzaneque JC, Thai SN, et al. Fibulin-1 acts as a cofactor for the matrix metalloprotease ADAMTS-1. J Biol Chem. 2005;280:34796–34804.
18. Hessler DJ, Newman C, Kim KW, Kimble J. GON-1 and fibulin have antagonistic roles in control of organ shape. Curr Biol. 2004;14:2005–2010.
19. Kubota Y, Kuroki R, Nishiwaki K. A fibulin-1 homolog interacts with an ADAM protease that controls cell migration in C. elegans. Curr Biol. 2004;14:2011–2018.
20. Klenuotic PA, Munier FL, Marmorstein LY, Anand-Apte B. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a binding partner of epithelial growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1). Implications for macular degenerations. J Biol Chem. 2004;279:30469–30473.

21. Albig AR, Neil JR, Schiemann WP. Fibulins 3 and 5 antagonize tumor angiogenesis in vivo. Cancer Res. 2006;66:2621–2629.

22. Rahn DD, Acevedo JE, Roshanravan S, et al. Failure of pelvic organ support in mice deficient in fibulin-3. Am J Pathol. 2009;174:206–215.

23. Kim EJ, Lee SY, Woo MK, et al. Fibulin-3 promoter methylation alters the invasive behavior of non-small cell lung cancer cell lines via MMP-7 and MMP-2 regulation. Int J Oncol. 2012;40:402–408.

24. Wang Z, Cao CJ, Huang LL, et al. EFEMP1 promotes the migration and invasion of osteosarcoma via MMP-2 with induction by AEG-1 via NF-kappaB signaling pathway. Oncotarget. 2015;6:14191–14208.

25. Fernandez-Godino R, Garland DL, Pierce EA. A local complement response by RPE causes early-stage macular degeneration. Human Mol Genet. 2015;24:5555–5569.

26. Klein T, Bischoff R. Physiology and pathophysiology of matrix metalloproteinases. Amino Acids. 2011;41:271–290.

27. Woessner JF Jr. That impis TIMP: the tissue inhibitor of metalloproteinases-3. Clin Investig. 2001;108:799–800.

28. Weber BH, Vogt G, Pruett RC, Stohr H, Felbor U. Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby’s fundus dystrophy. Nat Genet. 1999;4:352–356.

29. Capon M, Marshall J, Krafft JI, Alexander RA, Hiscott PS, Bird AC. Sorsby’s fundus dystrophy: a light and electron microscopic study. Ophthalmoimol. 1989;95:1769–1777.

30. Hussain AA, Lee Y, Zhang JJ, Marshall J. Disturbed matrix metalloproteinase activity of Bruch’s membrane in age-related macular degeneration. Invest Ophthal mol Vis Sci. 2011;52:4459–4466.

31. Grabb J, Miyagi M, Gu X, et al. Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc Natl Acad Sci U S A. 2002;99:14682–14687.

32. Marmorstein LY, Munier FL, Arsenijevic Y, et al. Aberrant accumulation of EFEMP1 underlies drusen formation in Malattia Leventinese and age-related macular degeneration. Proc Natl Acad Sci U S A. 2002;99:13067–13072.

33. Marmorstein LY, McLaughlin PJ, Peachey NS, Sasaki T, Marmorstein AD. Formation and progression of sub-retinal pigment epithelium deposits in Efemp1 mutation knock-in mice: a model for the early pathogenic course of macular degeneration. Human Mol Genet. 2007;16:2425–2432.

34. Fu L, Garland D, Yang Z, et al. The R345W mutation in EFEMP1 is pathogenic and causes AMD-like deposits in mice. Hum Mol Genet. 2007;16:2411–2422.

35. McLaughlin PJ, Bakall B, Choi J, et al. Lack of fibulin-3 causes early aging and herniation, but not macular degeneration in mice. Human Mol Genet. 2007;16:3059–3070.

36. Stanton JB, Marmorstein AD, Zhang Y, Marmorstein LY. Deletion of Efemp1 is protective against the development of sub-RPE deposits in mouse eyes. Invest Ophthal mol Vis Sci. 2017;58:1455–1461.

37. Scott JE. Morphometry of cupromeronic blue-stained protocglycan molecules in animal cornicas, versus that of purified protocglycans stained in vitro, implies that tertiary structures contribute to corneal ultrastructure. J Anatomy. 1992;180(pt 1):155–164.

38. Scott JE. Collagen–proteoglycan interactions. Localization of proteoglycans in tendons by electron microscopy. Biochem J. 1980;187:887–891.

39. Ho LT, Harris AM, Tanioka H, et al. A comparison of glycosaminoglycan distributions, keratan sulphate sulphation patterns and collagen fibril architecture from central to peripheral regions of the bovine cornea. Matrix Biol. 2014;38:59–68.

40. Hussain AA, Starita C, Hodggets A, Marshall J. Macromolecular diffusion characteristics of ageing human Bruch’s membrane: implications for age-related macular degeneration (AMD). Exp Eye Res. 2010;90:703–710.

41. Zayas-Santiago A, Marmorstein AD, Marmorstein LY. Relationship of stokes radius to the rate of diffusion across Bruch’s membrane. Invest Ophthal mol Vis Sci. 2011;52:4907–4913.

42. Lin Z, Wang Z, Li G, Li B, Xie W, Xiang D. Fibulin-3 may improve vascular health through inhibition of MMP-2/9 and oxidative stress in spontaneously hypertensive rats. Mol Med Rep. 2016;13:3805–3812.

43. Sun BS, Zhu X, Clayton MM, Pan J, Feitelson MA. Identification of a protein isolated from senescent human cells that binds to hepatitis B virus X antigen. Hepatology. 1998;27:228–239.

44. Lecka-Czernik B, Lumnkin CK Jr, Goldstein S. An overexpressed gene transcript in senescent and quiescent human fibroblasts encoding a novel protein in the epidermal growth factor-like repeat family stimulates DNA synthesis. Mol Cell Biol. 1995;15:120–128.

45. Curcio CA, Johnson M, Huang JD, Rudolf M. Aging, age-related macular degeneration, and the response-to-retention of apolipoprotein B-containing lipoproteins. Prog Retin Eye Res. 2009;28:393–422.

46. Rudolf M, Curcio CA. Esterified cholesterol is highly localized to Bruch’s membrane, as revealed by lipid histochemistry in whole mounts of human choroid. J Histochem Cytochem. 2002;50:731–739.

47. Curcio CA, Johnson M, Huang JD, Rudolf M. Apolipoprotein B-containing lipoproteins in retinal aging and age-related macular degeneration. J Lipid Res. 2010;51:451–467.

48. Curcio CA, Johnson M, Huang JD, Rudolf M. Oil spill in ageing Bruch membrane. Br J Ophthal mol. 2011;95:1638–1645.

49. Rudolf M, Seckerdieck K, Grisanti S, Curcio CA. Internal structure consistent with remodelling in very small drusen, revealed by filipin histochemistry for esterified cholesterol. Br J Ophthal mol. 2014;98:698–702.

50. Kunchithapautham K, Atkinson C, Rohrer B. Smoke exposure causes endoplasmic reticulum stress and lipid accumulation in retinal pigment epithelium through oxidative stress and complement activation. J Biol Chem. 2014;289:14534–14546.

51. Johnson LV, Forest DL, Banna CD, et al. Cell culture model that mimics drusen formation and triggers complement activation associated with age-related macular degeneration. Proc Natl Acad Sci U S A. 2011;108:18277–18282.

52. Garland DL, Fernandez-Godino R, Kaur I, et al. Mouse genetics and protemic analyses demonstrate a critical role for complement in a model of DRHD/ML, an inherited macular degeneration. Human Mol Genet. 2014;23:52–68.

53. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol. 1995;15:551–561.

54. Handa JT, Cano M, Wang L, Datta S, Liu T. Lipids, oxidized lipids, oxidation-specific epitopes, and age-related macular degeneration. Biochim Biophys Acta. 2017;1862:430–440.